OSR Holdings, Inc. 8-K

What Happened
OSR Holdings, Inc. announced on May 27, 2026 that it entered into an Asset Purchase Agreement with Vaximm AG (an indirect subsidiary) to acquire all rights to the VXM01 intellectual property family. The $30,000,000 purchase price is due in full when the first milestone under a related Global Exclusive License Agreement is triggered — defined as completion of a Phase 2 clinical study of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC). The deal is a related‑party transaction and the closing will occur upon full payment and delivery of IP assignment documents, subject to customary conditions.

Key Details

• Purchase price: $30,000,000, stated as the fair market value of the Purchased Assets.
• Payment timing: Full amount due on the date the first milestone under the April 29, 2026 License Agreement is triggered (completion of a Phase 2 study in GBM or PDAC); voluntary partial payments allowed earlier.
• Assets included: VXM01 patents and patent applications, know‑how, regulatory filings, clinical data and certain related assigned contracts.
• Other terms: Default only occurs if OSR fails to pay on the Full Payment Due Date; agreement may be terminated if closing hasn’t occurred by December 31, 2027; governed by Swiss law.

Why It Matters
If and when the purchase closes, OSR would become the direct owner of the VXM01 IP and the direct beneficiary of future milestone and royalty payments under the existing License Agreement, potentially simplifying future revenue flows tied to VXM01. The $30M price is structured to be payable upon a clinical milestone (Phase 2 completion), so there is no immediate required cash outlay unless OSR elects voluntary payments. Investors should note this is a related‑party transfer (Vaximm is an indirect subsidiary) and that the timing and financial impact depend on clinical progress for VXM01.